Improvement in symptoms after H2-receptor antagonist-based therapy for eradication of H pylori infection

Table 1 Demographic characteristics of the patients

		Lafutidinegroup	Lansoprazolegroup	P
No. of patients		20	20	-
Sex (male:female)		13:7	14:6	NS
Mean age (range)		51.1 (22-66)	50.6 (20-79)	NS
Site of ulcer (gastric ulcer:duodenal ulcer)		12:8	10:10	NS
History of ulcer	Initial onset	3	5	NS
	Recurrence	15	14
	Unknown	2	1
Pretreatment within	None	15	13	NS
1 wk before treatment	Done	3	6
	Unknown	2	1
Pretreatment with an H2-receptor antagonist	None	14	14	NS
	Done	6	6
CYP2C19		6:9:1:4	5:8:6:1 P < 0.05
(homoEM : heteroEM:PM:Unknown)
Sensitive or resistant to clarithromycin		16:1:3	15:1:4	NS
Sensitive (MIC < 1) resistant:(MIC ≥ 1):Unknown

HomoEM: homozygous-extensive metabolizer; heteroEM: hetreozygous-extensive metabolizer; PM: poor metabolizer; MIC: minimal inhibitory concentration.

Table 2 Eradication rate of H pylori

		Lafutidine group	Lansoprazole group	P
Intention-to-treat analysis
	No. of patients	24	22	-
	Eradication rate	16/24 (66.7%)	16/22 (72.7%)	NS
Per-protocol analysis
	No. of patients	20	20	-
	Eradication rate	14/20 (70.0%)	14/20 (70.0%)	NS

Table 3 Eradication rate according to type of CYP2C19 polymorphism

	Lafutidine group	Lansoprazole group	P
Homo EM	5/6 (83%)	3/5 (60%)	NS
Hetero EM	6/9 (67%)	6/8 (75%)	NS
PM	1/1 (100%)	5/6 (83%)	NS

HomoEM: homozygous-extensive metabolizer; HeteroEM: hetreozygous-extensive metabolizer; PM: poor metabolizer.

Table 4 Incidence of adverse events

		Lafutidine group	Lansoprazole group	P
Adverse events	Not present	17	17	NS
	Present	3	3
Incidence of adverse events		15.0% (3/20)	15.0% (3/20)
Adverse events	Stomatitis		3	NS
	Diarrhea	1	1
	Constipation	1
	Throat pain		1
	Drug rash	1
	Taste disorder		1